Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Overview of attention for article published in Infectious Diseases and Therapy, October 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#9 of 1,075)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 15 news outlets
policy: 2 policy sources
twitter: 223 X users
patent: 3 patents

facebook: 1 Facebook page
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 296 Mendeley

So far, Altmetric has seen 244 X posts from 223 X users, with an upper bound of 527,500 followers.

RT @CADarlow: This happens even with newer agents. In the clinical trials for testing meropenem-vaborbactam and cefidercol for HAP, whilst…

This happens even with newer agents. In the clinical trials for testing meropenem-vaborbactam and cefidercol for HAP, whilst both produced a successful trial outcome, emergence of resistance to both was seen in each trial. https://t.co/c6Komo2qlQ https:…

Fourth study was on clinical experience with meropenem/vaborbactam from Italy. Single center, prospective, observational. Limited data on its use after tango 2. @Sara_Alosaimy @ryankshields work got a shout out #ECCMID2023 https://t.co/FdBeyTTP6I http…

RT @litalkat: לא דמי ייעוץ, מענקי מחקר ודמי הרצאה מפייזר. ובטח שלא תרומות. מעתה אמרו: "כל מיני הכנסות שהתפתחו לאנשים". לפחות עבור פרופ' גלי…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 240 additional X posts.